A first in-human study of A166 in patients with locally advanced/metastatic solid tumors which are HER2-positive or HER2-amplified who did not respond or stopped responding to approved therapies.
Yongheng Liu(Kelun Group (China)), Jingyi Wang(Qingdao University), Qing Yan(Kelun Group (China)), Xi Zhao(Chongqing Medical University), Wei‐Xiang Qi(East China University of Science and Technology), Tongtong Xue(Beijing Institute of Technology), Xiao Liang(Kelun Group (China)), Wei Lian(Kelun Group (China)), Jian Xu(University of California, Los Angeles)
Cited by 50
Related Papers
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer
|Gastric Cancer|2014|615
Circulating MicroRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis
|Molecular Carcinogenesis|2010|558
Drug resistance to targeted therapeutic strategies in non-small cell lung cancer
|Pharmacology & Therapeutics|2019|245
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
|Cancer Cell|2014|208